- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07948629
Stressor-Focused Therapy for Emotional Processing in Adjustment Disorder (STEP)
STEP - Stressor-focused Therapy for Emotional Processing in ICD-11 Adjustment Disorder: A Randomised Waitlist-Controlled Trial
This randomized controlled trial evaluates the efficacy of STEP, a brief 12-session psychotherapy for adults with ICD-11 Adjustment Disorder (AjD). STEP is a manualized, CBT-based, event-focused intervention designed to reduce Adjustment Disorder symptoms and support adaptive emotional processing and coping. Participants in the waitlist control group will receive STEP after the 12-week waiting period. Outcomes will be assessed at baseline, post-treatment, and at a 3-month follow-up. The primary outcome is Adjustment Disorder symptom severity. Secondary outcomes include perceived stress, depression, anxiety, well-being, and experiential avoidance.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Adjustment disorder (AjD) is characterised in ICD-11 by two core symptom clusters: preoccupation with the stressor and failure to adapt. Although adjustment disorder is frequently diagnosed in clinical practice, evidence for disorder-specific psychological treatments based on the ICD-11 conceptualisation remains limited.
STEP (Stressor-focused Therapy for Emotional Processing) was developed to address these core symptoms through a structured, event-focused cognitive-behavioural approach. The treatment is based on the conceptualisation of adjustment disorder as a stress-response syndrome, in which persistent preoccupation with a stressful life event and avoidance of associated memories, thoughts, and emotions may contribute to symptom maintenance.
Drawing on established cognitive-behavioural and trauma-focused treatment principles, STEP integrates psychoeducation, individual case formulation, emotional awareness and regulation, event-focused imaginal exposure, cognitive restructuring, resource activation, and adaptive coping strategies. A central component is the guided emotional processing of distressing life events and emotionally salient moments associated with the stressor. The intervention aims to reduce maladaptive avoidance and preoccupation, facilitate emotional processing, and support adaptation to changed life circumstances.
This randomised waitlist-controlled trial evaluates the efficacy of STEP in adults diagnosed with ICD-11 adjustment disorder. The primary hypothesis is that participants receiving STEP will demonstrate greater reductions in adjustment disorder symptoms than participants assigned to the waitlist condition. Secondary objectives include examining changes in psychological distress, experiential avoidance, and subjective well-being, as well as evaluating treatment feasibility and acceptability.
The study is expected to contribute to the development of targeted, evidence-based psychotherapeutic interventions for adjustment disorder.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Rahel Bachem, Prof. Dr.
- Telefonnummer: +41 58 257 35 26
- E-post: rahel.bachem@ost.ch
Studiesteder
-
-
Canton of St. Gallen
-
Sankt Gallen, Canton of St. Gallen, Sveits, 9001
- Competence Center for Mental Health; Eastern Switzerland University of Applied Sciences
-
Ta kontakt med:
- Rahel Bachem, Prof. Dr.
- Telefonnummer: +41 58 257 35 26
- E-post: rahel.bachem@ost.ch
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age ≥ 18 years
- Diagnosis of ICD-11 Adjustment Disorder confirmed via structured clinical interview using the IADQ diagnostic algorithm
- Presence of a clearly identifiable psychosocial stressor 2 weeks to 2 years before participation
- Sufficient German language proficiency to participate in psychotherapy and complete study assessments
- Capacity to provide written informed consent
Exclusion Criteria:
- Current PTSD or CPTSD meeting ICD-11 diagnostic criteria following a Criterion A traumatic event
- Current prolonged grief disorder meeting ICD-11 diagnostic criteria
- Lifetime history of bipolar disorder or psychotic disorder, including schizophrenia spectrum disorders
- Severe depressive or anxiety symptoms clearly predating the identified stressor and judged to better account for the current clinical presentation
- Another severe mental disorder that would interfere with participation in psychotherapy or better explain the presenting symptoms
- Acute suicidality requiring immediate crisis intervention
- Ongoing psychotherapy
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: STEP Intervention Group
Participants assigned to the intervention group receive 12 weekly sessions of the STEP psychotherapy intervention after completion of the baseline assessment. |
STEP is a brief, manualized, 12-session CBT-based psychotherapy specifically developed for ICD-11 Adjustment Disorder (AjD). It follows a staged, event-focused approach targeting the core symptom clusters of preoccupation and failure to adapt. Treatment components include psychoeducation and individualized case conceptualization, emotional awareness and regulation skills, stressor-focused imaginal exposure and emotional processing, cognitive and emotional reprocessing of stressor-related meanings, strengthening of personal resources and adaptive coping strategies, and relapse prevention. |
|
Annen: Waitlist Control Group
Participants assigned to the waitlist control group do not receive the STEP intervention during the 12-week waiting period. After completion of the waiting period, participants receive the STEP intervention. |
STEP is a brief, manualized, 12-session CBT-based psychotherapy specifically developed for ICD-11 Adjustment Disorder (AjD). It follows a staged, event-focused approach targeting the core symptom clusters of preoccupation and failure to adapt. Treatment components include psychoeducation and individualized case conceptualization, emotional awareness and regulation skills, stressor-focused imaginal exposure and emotional processing, cognitive and emotional reprocessing of stressor-related meanings, strengthening of personal resources and adaptive coping strategies, and relapse prevention. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Adjustment Disorder Symptom Severity at Post-Treatment
Tidsramme: Week 12-14 after baseline (T1; post-treatment in the immediate intervention group and post-waiting period in the control group)
|
Adjustment disorder symptom severity is assessed using the International Adjustment Disorder Questionnaire (IADQ). The primary outcome is the sum of six symptom items (Items 1-6), covering preoccupation with the stressor and failure to adapt. Each item is rated from 0 to 4, resulting in a total score ranging from 0 to 24, with higher scores indicating greater symptom severity. Scores at T1 will be compared between groups, adjusting for baseline scores. |
Week 12-14 after baseline (T1; post-treatment in the immediate intervention group and post-waiting period in the control group)
|
|
Depressive Symptom Severity
Tidsramme: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
Assessed using the International Depression Questionnaire (IDQ), measuring depressive symptoms according to ICD-11. |
Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Anxiety Symptom Severity
Tidsramme: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
Assessed using the International Anxiety Questionnaire (IAQ), measuring symptoms of generalized anxiety according to ICD-11. |
Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
|
Perceived Stress
Tidsramme: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
Assessed using the 10-item Perceived Stress Scale (PSS-10), measuring the perceived level of stress. |
Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
|
Subjective Well-Being
Tidsramme: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
Assessed using the World Health Organization-Five Well-Being Index (WHO-5), measuring subjective psychological well-being. |
Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
|
Experiential Avoidance
Tidsramme: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
Assessed using the Brief Experiential Avoidance Questionnaire (BEAQ), measuring the tendency to avoid unwanted internal experiences. |
Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
|
Adjustment Disorder Diagnostic Status
Tidsramme: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
Assessed through a structured clinical interview evaluating the presence or absence of ICD-11 adjustment disorder and diagnostic remission. |
Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
|
Treatment Credibility and Expectancy
Tidsramme: Immediately after STEP Session 1
|
Assessed using the Credibility/Expectancy Questionnaire (CEQ), measuring treatment credibility and expected improvement. |
Immediately after STEP Session 1
|
|
Treatment Acceptability and Feasibility
Tidsramme: Immediately after completion of the 12-session STEP treatment
|
Assessed using the Treatment Feedback and Adherence questionnaire (TFA), evaluating participants' experiences with STEP. |
Immediately after completion of the 12-session STEP treatment
|
|
Event-Focused Repetitive Thoughts
Tidsramme: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
Assessed using the Event-focused Repetitive Thoughts Questionnaire (ERTQ), measuring repetitive thoughts related to stressful life events. |
Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Bachem R, Maercker A. Self-help interventions for adjustment disorder problems: a randomized waiting-list controlled study in a sample of burglary victims. Cogn Behav Ther. 2016 Sep;45(5):397-413. doi: 10.1080/16506073.2016.1191083. Epub 2016 Jun 14.
- Levin Y, Bachem R, Hyland P, Karatzias T, Shevlin M, Ben-Ezra M, Maercker A. Validation of the International Adjustment Disorder Questionnaire in Israel and Switzerland. Clin Psychol Psychother. 2022 Jul;29(4):1321-1330. doi: 10.1002/cpp.2710. Epub 2022 Jan 20.
- Bachem R, Casey P. Adjustment disorder: A diagnosis whose time has come. J Affect Disord. 2018 Feb;227:243-253. doi: 10.1016/j.jad.2017.10.034. Epub 2017 Oct 23.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- STEP_PILOTSTUDY
- PT0041_222855 (Annet stipend/finansieringsnummer: Swiss National Science Foundation - SNSF)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
A fully anonymized individual participant dataset will be made available in a publicly accessible scientific repository (e.g., OSF) following publication of the primary study results. All direct identifiers will be removed, and indirect identifiers will be minimized to prevent re-identification. No identifiable or coded participant data will be shared.
IPD-delingstidsramme
The anonymized individual participant dataset will become publicly available following publication of the primary study results. The dataset will remain accessible for as long as it is maintained in the selected public scientific data repository.
Tilgangskriterier for IPD-deling
The fully anonymized dataset will be publicly accessible to researchers and other interested users through an open scientific data repository, such as the Open Science Framework (OSF), without an individual access request. The shared dataset will contain numerical questionnaire data and broadly categorized demographic information. Free-text descriptions, exact age, geographical information, direct identifiers, and coded participant data will not be made publicly available. A data dictionary will accompany the dataset.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .